Management of acute seizure and status epilepticusthaiepilepsysociety.com/wp...of-acute-seizure-and-status-epilepticus...pdf · “Status epilepticus is a condition resulting either

Management of acute seizure and status epilepticus

Apisit Boongird, MD

Division of Neurology

Ramathibodi Hospital

Sunday August 27 10.00-10.45

Bangsan

Objectives

• Acute repetitive seizure

• Status epilepticus

Definition of epileptic seizure by the

International League Against Epilepsy (ILAE)

• An epileptic seizure is a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain.

Epilepsia, 46(4):470–472, 2005

Acute repetitive seizures (Seizure clusters)

Acute repetitive seizures (ARS)

• Home

• OPD

• IPD

Acute Repetitive Seizures (ARS)

• The practical definition of acute repetitive seizures has not been established.

• Acute repetitive seizures is neurologic emergency and a common clinical phenomenon describing an increase in seizures occurring over a specific period of time (ranging from several minutes up to 24 hours).

• Acute repetitive seizures may include any type of seizure and may vary in severity, but by definition there is complete recovery in between seizures.

Curr Opin Neurol 2015;28(2):143Y150.

Management of acute repetitive seizures (ARS)

• Stop the seizures

• Identify the etiology of acute repetitive seizures

• Benzodiazepines remain the mainstay of therapy.

• The treatment of ARS includes the usage of extra doses of usual antiepileptic medications and oral benzodiazepines (diazepam or lorazepam) for mild ARS.

• A 45 yo presented with first unprovoked seizures.

seizure type 1: left face clonic with preserved awareness

seizure duration: 5 minutes

Treatment: LEV 500-500 + sx

• In August 2560, he had ARS for 2 hours.

Outpatient acute benzodiazepine therapy

• Rectal diazepam is the only currently marketed treatment available for use by nonmedical caregivers in the USA, and buccal midazolam is approved in the European Union.

Outpatient acute benzodiazepine therapy

Medications Formulation Notes

Diazepam oral tablet

rectal gel (FDA approved) N Engl J Med 1998;

338:1869–1875. and Neurology 1998; 51:1274–1282.

intramuscular

Midazolam buccal

intranasal

intramuscular N Engl J Med 2012;

366:591–600 (The Rapid Anticonvulsant Medication Prior to Arrival

Trial (RAMPART) in pre-hospital status epilepticus

Lorazepam oral tablet

intranasal

sublingual

Progesterone cyclic natural progesterone catamenial epilepsy Neurology 2014; 83:345–348.

CNS Drugs (2015) 29:55–70

Oromucosal midazolam (solution Buccolam)

https://www.medicines.org.uk

Age range Dose Label colour

3 to 6 months hospital setting 2.5 mg Yellow

> 6 months to < 1 year 2.5 mg Yellow

1 year to < 5 years 5 mg Blue

5 years to < 10 years 7.5 mg Purple

10 years to < 18 years 10 mg Orange

Standard doses are indicated below:

Carers should only administer a single dose of midazolam. If the seizure has not stopped within 10 minutes after

Status epilepticus (SE)

Old definition of SE

• A definition of more than 30 minutes of continuous seizure activity or two or more sequential seizures without full recovery of consciousness between was widely adopted, citing neuronal damage in animal models beyond this timeframe.

Epilepsy Foundation, 1993

Cerebral changes Systemic and metabolic

changes

Autonomic and

cardiovascular changes

increased cerebral blood flow hyperglycemia increased blood pressure

increased cerebral

metabolism

lactic acidosis increased cardiac output

increased lactate

concentration

massive catecholamine

release

increased glucose

concentration

cardiac dysthymia

urine incontinence

Phase 1: compensation

J Neurol Neurosurg Psychiatry 2001;70(suppl II):ii22–ii27

Phase 2: decompensation

Cerebral changes Systemic and metabolic

changes

Autonomic and

cardiovascular changes

failure of cerebral

autoregulation

hypoglycemia hypoxia

hypoxia hypokalemia/ hyperkalemia falling blood pressure

hypoglycemia metabolic and respiratory

acidosis

falling cardiac output

increased intracranial

pressure and cerebral oedema

hepatic and renal dysfunction cardiac failure

consumptive coagulopathy respiratory failure

DIC hyperpyrexia

rhabdomyolysis,

myoglobinuria

J Neurol Neurosurg Psychiatry 2001;70(suppl II):ii22–ii27

“Status epilepticus is a condition resulting either from the failure of the mechanisms

responsible for seizure termination or from the initiation of mechanisms, which lead to

abnormally, prolonged seizures (after time point t1). It is a condition, which can have

long-term consequences (after time point t2), including neuronal death, neuronal injury,

and alteration of neuronal networks, depending on the type and duration of seizures”.

Epilepsia, 56(10):1515–1523, 2015

• Status epilepticus represents the persistence of abnormal excitation and the ineffective recruitment of inhibition.

J Clin Neurophysiol1995;12(4):326Y342.

Type of SE Operational dimension 1

Time (t1), when a seizure is

likely to

be prolonged leading to

continuous

seizure activity

Operational dimension 2

Time (t2), when a seizure may

cause long term consequences

(including neuronal injury,

neuronal death, alteration

of neuronal networks and

functional deficits)

Tonic- clonic SE 5 min 30 min

Focal SE with

impaired

consciousness

10 min > 60 min

Absence status

epilepticus

10-15 mina unknown

Epilepsia, 56(10):1515–1523, 2015a= Evidence for the time frame is currently limited and future data may lead to modifications

Classification of SE by the ILAE

• 1 Semiology

• 2 Etiology

• 3 EEG correlates

• 4 Age

Epilepsia, 56(10):1515–1523, 2015

Axis 1: Semiology

• The presence or absence of prominent motor symptoms

• The degree (qualitative or quantitative) of impaired consciousness

Epilepsia, 56(10):1515–1523, 2015

Axis 1: Classification of status epilepticus (SE)

A) With prominent motor symptoms

A.1 Convulsive SE (CSE, synonym: tonic–clonic SE)

A.1.a. Generalized convulsive

A.1.b. Focal onset evolving into bilateral convulsive SE

A.1.c. Unknown whether focal or generalized

A.2 Myoclonic SE (prominent epileptic myoclonic jerks)

A.2.a. With coma

A.2.b. Without coma

A.3 Focal motor

A.3.a. Repeated focal motor seizures (Jacksonian)

A.3.b. Epilepsia partialis continua (EPC)

A.3.c. Adversive status

A.3.d. Oculoclonic status

A.3.e. Ictal paresis (i.e., focal inhibitory SE)

A.4 Tonic status

A.5 Hyperkinetic SE

Epilepsia, 56(10):1515–1523, 2015

(B) Without prominent motor symptoms (i.e., nonconvulsive SE, NCSE)

B.1 NCSE with coma (including so-called “subtle” SE)

B.2 NCSE without coma

B.2.a. Generalized

B.2.a.a Typical absence status

B.2.a.b Atypical absence status

B.2.a.c Myoclonic absence status

B.2.b. Focal

B.2.b.a Without impairment of consciousness (aura continua, with autonomic, sensory,

visual, olfactory, gustatory, emotional/ psychic/experiential, or auditory symptoms)

B.2.b.b Aphasic status

B.2.b.c With impaired consciousness

B.2.c Unknown whether focal or generalized

B.2.c.a Autonomic SE


Epilepsia, 56(10):1515–1523, 2015

Axis 2: Etiology

• Known (i.e., symptomatic)

- Acute (e.g., stroke, intoxication, malaria, encephalitis, etc.)

- Remote (e.g., posttraumatic, postencephalitic, poststroke, etc.)

- Progressive (e.g., brain tumor, Lafora’s disease and other PMEs, dementias)

- SE in defined electroclinical syndromes

• Unknown (i.e., cryptogenic)

Epilepsia, 56(10):1515–1523, 2015

Axis 3: Electroencephalographic correlates

• Currently there are no evidence-based EEG criteria for SE.

Epilepsia, 56(10):1515–1523, 2015

EEG patterns in SE

1. Location: generalized (including bilateral synchronous patterns), lateralized, bilateral independent,

multifocal.

2. Name of the pattern: Periodic discharges, rhythmic delta activity or spike-and-wave/sharp- and-wave

plus subtypes.

3. Morphology: sharpness, number of phases (e.g., triphasic morphology), absolute and relative amplitude,

polarity.

4. Time-related features: prevalence, frequency, duration, daily pattern duration and index,

onset (sudden vs. gradual), and dynamics (evolving, fluctuating, or static).

5. Modulation: stimulus-induced vs. spontaneous.

6 Effect of intervention (medication) on EEG.

Epilepsia, 56(10):1515–1523, 2015

Axis 4: Age

1. Neonatal (0 to 30 days)

2. Infancy (1 month to 2 years)

3. Childhood (> 2 to 12 years)

4. Adolescence and adulthood (> 12 to 59 years)

5. Elderly (≥ 60 years)

Epilepsia, 56(10):1515–1523, 2015

Generalized convulsive status epilepticus (GCSE)

Definition of CSE

• CSE is a convulsive seizure lasting more than 5 min or consecutive seizures without recovery of consciousness.

• In the case of convulsive SE, both time points (t1 at 5 min and t2 at 30 min) are based on animal experiments and clinical research.

Epilepsia, 56(10):1515–1523, 2015

Key points

• Principle of treatment

1. Stop both ongoing clinical and electrographic seizures

2. Identify and treat the etiology of CSE

3. diagnosis and treatment of complications of CSE

Time is the brain

• The response to treatment with anti-seizure medications is decreasing with time and ongoing seizures probably due to the following reasons;

- internalization of GABA receptors

- the upregulation of drug-efflux transporters such as P- glycoprotein

- an increment of pro-inflammatory agents

Ann N Y Acad Sci 2016;1378:166–73.

Epilepsia 2009;50(Suppl. 8):19–21.

Choosing the anti-seizure medications

• Age

• Clinical seizure type

• Comorbidities

- cardiovascular disease

- liver disease

- kidney disease

• History of drug allergy

- minor rash to SJSs

• Anti-seizure medications

- administration

- mechanism of action

- pharmacodynamics

- pharmacokinetics

- efficacy for each seizure type

- recommended doses

- adverse effects

- drug interactions

Treatment phases of CSE

• Stage 1 (early or impending CSE)

- Benzodiazepines are the drugs of choice.

- RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial)

IV lorazepam vs IM midazolam*

- AES guideline state that IM midazolam has a superior effectiveness

compared to intravenous lorazepam in adults with CSE without

established intravenous access (Level A)***N Engl J Med 2012; 366:591-600

**Epilepsy Curr 2016;16:48–61.


• Stage 2 (Established SE) : CSE persisting after first-line treatments

- phenytoin (fosphenytoin)

- phenobarbital

- valproic acid

- levetiracetam

- lacosamide


• Stage 3 (refractory CSE): CSE persisting > 60 minutes after second-line treatments

- Hemodynamic monitoring

- EEG monitoring

- Initiation of anesthetic agents

- Midazolam

- Propofol

- Thiopental

- Ketamine

- Goals

- stop ongoing seizure

- EEG background suppression VS burst suppression

Therapeutic monitoring

• Objectives

- to monitor the therapeutic response

- to avoid side effects of therapy

• Hemodynamic and respiratory monitoring

- pulse oximetry

- monitor Bp, HR, O2 sat

- EKG monitoring

• Clinical neurophysiologic test

- Continuous EEG monitoring


• Stage 3 (refractory CSE): CSE persisting after second-line treatments

- Anesthetic agents are the drugs of choice for the treatment of refractory CSE. It is required to secure the airway and start mechanical ventilation if the patient is not already intubated for other reasons.

- If no seizure for 24- 48 hours, then tapering off anesthetic agents

- Adequate anti-seizure medications should be prescribed to the patient while the anesthetic agent is being withdrawn.

- avoid anti-seizure medications with a primarily GABAergic mechanism

- avoid > 2 anti-seizure medications

- try anti-seizure medications with multiple mechanisms of action and low drug interactions

NeurocritCare 2012;17:3–23.


• Stage 4 (super-refractory CSE)*: CSE persisting for more than 24 hours after administration of third-line treatments

- anesthetic agents

- ketamine

- immunomodulatory therapy

- hypothermia

- new anti-seizure medications

- ketogenic diet*

*Brain 2011;134:2802–18.

**Neurology. 2017 Mar 7;88(10):938-943.

The US Department of Veterans Affairs (VA) Cooperative Study randomized controlled clinical trial

N Engl J Med 1998;339(12):792Y798

Conclusions

As initial intravenous treatment for overt generalized convulsive status epilepticus, lorazepam is more effective

than phenytoin. Although lorazepam is no more efficacious than phenobarbital or diazepam and phenytoin, it is

easier to use.

518 pts with GCSE

Five-year randomized, double blind, multicenter trial of four intravenous regimens

1.Lorazepam 2.Phenobarbital 3.Phenytoin 4. Diazepam

followed by Phenytoin

Classified into

1. Overt SE (n=384 pts)

2. Subtle SE (n= 134 pts)

http://thaiepilepsysociety.com






Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society

Epilepsy Currents, Vol. 16, No. 1 (January/February) 2016 pp. 48–61

Epilepsy Currents, Vol. 16, No. 1 (January/February) 2016 pp. 48–61

Phenytoin in GCSE

• Efficacy

• Administration

• Adverse effects

• Allergy

• Enzyme inducing properties

NeurocritCare 2013;18:193–200.

The Established Status Epilepticus Treatment Trial (ESETT)

• This ESETT is currently enrolling patients and is designed to determine the most effective and/or the least effective treatment of ESE among patients older than 2 years by comparing three arms: fosphenytoin (fPHT), levetiracetam (LVT), and valproic acid (VPA).

Epilepsia 2013;54:89–92.

Non-convulsive status epilepticus (NCSE)

Non-convulsive status epilepticus (NCSE)

• Patients with NCSE may have no clinical signs or develop only subtle jerks of the face, eyes, and extremities.

• NCSE is diagnosed only by electroencephalography(EEG).

(B) Without prominent motor symptoms (i.e., nonconvulsive SE, NCSE)

B.1 NCSE with coma (including so-called “subtle” SE)

B.2 NCSE without coma

B.2.a. Generalized

B.2.a.a Typical absence status

B.2.a.b Atypical absence status

B.2.a.c Myoclonic absence status

B.2.b. Focal

B.2.b.a Without impairment of consciousness (aura continua, with autonomic, sensory,

visual, olfactory, gustatory, emotional/ psychic/experiential, or auditory symptoms)

B.2.b.b Aphasic status

B.2.b.c With impaired consciousness

B.2.c Unknown whether focal or generalized

B.2.c.a Autonomic SE


Epilepsia, 56(10):1515–1523, 2015

Salzburg EEG consensus criteria for nonconvulsive status epilepticus (SCNC)

Lancet Neurol 2016;15(September (10)) 1054–62Epilepsy Behav: E&B 2015;49(August)158–63

Patients without known epileptic encephalopathy

• EDs > 2.5 Hz, or

• EDs ≤ 2.5 Hz or rhythmic delta/theta activity (> 0.5Hz) AND one of the following:

- EEG and clinical improvement after IV AED*, or

- Subtle clinical ictal phenomena, or

- Typical spatiotemporal evolution**

Patients with known epileptic encephalopathy

• Increase in prominence or frequency when compared to baseline with observable change in clinical state

• Improvement of clinical and EEG* features with IV AEDs

* If EEG improvement without clinical improvement, or if fluctuation without definite evolution, this should be

considered possible NCSE.

** Increment onset(increase in voltage and change in frequency), or evolution in pattern(change in frequency >

1Hz or change in location), or decrementing termination(voltage and frequency).

EDs: epileptiform discharges(spikes, polyspikes, sharp-waves, sharp-and-wave complexes)

IV AED: intravenous antiepileptic drugs

• A 17-yo male with past medical history of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke (MELAS) syndrome presents to the emergency department with status epilepticus for 30 minutes.

MELAS

midazolam + levetiracetam

American Clinical Neurophysiology Society’s Standardized Critical Care EEG Terminology: 2012 version

J Clin Neurophysiol 2013;30: 1–27

Epilepsy & Behavior 49 (2015) 158–163

Epilepsy & Behavior 49 (2015) 158–163

Epilepsia partialis continua (EPC)


• Prevalence 1: 1,000,000

• 5-10 patients per year at Faculty of Medicine, Prince of SongklaUniversity

• Segmental myoclonic seizures

• The most frequent distribution of EPC involved the face and arms (42.7%)

Paiboonpol S.J Med Assoc Thai. 2005 Jun;88(6):759-62

Epilepsy Res. 2012 Jun;100(1-2):179-87.


• Treatment

- identify and treat causal or precipitating factors

- anti-seizure medications

- first-generation: carbamazepine, valproate,

clonazepam

- second-generation: topiramate, levetiracetam

Conclusions

• Status epilepticus (SE) requires not only urgent symptomatic treatment with antiepileptic drugs but also rapid identification and treatment of its cause.

The end

Documents

Management of acute seizure and status epilepticusthaiepilepsysociety.com/wp...of-acute-seizure-and-status-epilepticus...pdf · “Status epilepticus is a condition resulting either